UNITY Biotechnology expands trial of osteoarthritis senolytic
UBX0101 currently in phase 1 trial for osteoarthritis (OA) of the knee.
UNITY Biotechnology encouraged by the safety and tolerability results so far.
Enrolling an additional 24 patients at the highest evaluated dose (4mg).
Part B of trial will provide an increased sample size for SASP assessment .
Will enable further evaluation the impact of UBX0101 on SASP.
Human clinical trial is the first study of a senolytic drug in patients with OA.